Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG, Pittner R, Jodka C, Smith P, Young A. Parkes DG, et al. Among authors: jodka c. Metabolism. 2001 May;50(5):583-9. doi: 10.1053/meta.2001.22519. Metabolism. 2001. PMID: 11319721
Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
Levy OE, Jodka CM, Ren SS, Mamedova L, Sharma A, Samant M, D'Souza LJ, Soares CJ, Yuskin DR, Jin LJ, Parkes DG, Tatarkiewicz K, Ghosh SS. Levy OE, et al. Among authors: jodka cm. PLoS One. 2014 Feb 4;9(2):e87704. doi: 10.1371/journal.pone.0087704. eCollection 2014. PLoS One. 2014. PMID: 24503632 Free PMC article.
Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.
Trevaskis JL, Mack CM, Sun C, Soares CJ, D'Souza LJ, Levy OE, Lewis DY, Jodka CM, Tatarkiewicz K, Gedulin B, Gupta S, Wittmer C, Hanley M, Forood B, Parkes DG, Ghosh SS. Trevaskis JL, et al. Among authors: jodka cm. PLoS One. 2013 Oct 22;8(10):e78154. doi: 10.1371/journal.pone.0078154. eCollection 2013. PLoS One. 2013. PMID: 24167604 Free PMC article.
Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.
Sun C, Trevaskis JL, Jodka CM, Neravetla S, Griffin P, Xu K, Wang Y, Parkes DG, Forood B, Ghosh SS. Sun C, et al. Among authors: jodka cm. J Med Chem. 2013 Nov 27;56(22):9328-41. doi: 10.1021/jm401418s. Epub 2013 Nov 6. J Med Chem. 2013. PMID: 24144329
Synthesis & biological evaluation of PYY(3-36) analogs substituted with alanine.
Ahn JS, Nazarbaghi R, D'Souza LJ, Ghosh S, Jodka CM, Lwin AN, Levy OE. Ahn JS, et al. Among authors: jodka cm. Adv Exp Med Biol. 2009;611:515-6. doi: 10.1007/978-0-387-73657-0_224. Adv Exp Med Biol. 2009. PMID: 19400291 No abstract available.
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Gedulin BR, et al. Among authors: jodka cm. Int J Pharm. 2008 May 22;356(1-2):231-8. doi: 10.1016/j.ijpharm.2008.01.015. Epub 2008 Jan 17. Int J Pharm. 2008. PMID: 18291606
Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.
Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG. Roth JD, et al. Among authors: jodka cm. Endocrinology. 2007 Dec;148(12):6054-61. doi: 10.1210/en.2007-0898. Epub 2007 Aug 30. Endocrinology. 2007. PMID: 17761760
Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Hargrove DM, et al. Regul Pept. 2007 Jun 7;141(1-3):113-9. doi: 10.1016/j.regpep.2006.12.021. Epub 2007 Jan 11. Regul Pept. 2007. PMID: 17292977
PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice.
Adams SH, Lei C, Jodka CM, Nikoulina SE, Hoyt JA, Gedulin B, Mack CM, Kendall ES. Adams SH, et al. Among authors: jodka cm. J Nutr. 2006 Jan;136(1):195-201. doi: 10.1093/jn/136.1.195. J Nutr. 2006. PMID: 16365082
Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187.
Gedulin BR, Jodka CM, Herrmann K, Young AA. Gedulin BR, et al. Regul Pept. 2006 Dec 10;137(3):121-7. doi: 10.1016/j.regpep.2006.06.004. Epub 2006 Aug 17. Regul Pept. 2006. PMID: 16914214
19 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback